Search research articles
Contact Us
Filters
Showing results (891-900 of 922) with videos related to
Page
of 93
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Blood Advances
|
October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Joshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.
Journal of Medical Genetics
|
April 12, 2014
A meta-analysis identifies adolescent idiopathic scoliosis association with LBX1 locus in multiple ethnic groups
Douglas Londono, Ikuyo Kou, Todd A Johnson, et al.
Clinical Kidney Journal
|
March 24, 2025
Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases
Jeffery C H Chan, Eugene Yu-Hin Chan, Samuel M S Cheng, et al.
Kidney International Reports
|
November 29, 2023
Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
Daniel Leung, Eugene Yu-Hin Chan, Xiaofeng Mu, et al.
American Journal of Hematology
|
August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
Anthony R Mato, Lindsey E Roeker, John N Allan, et al.
The New England Journal of Medicine
|
June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
John C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Signal Transduction and Targeted Therapy
|
December 14, 2022
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents
Xiaofeng Mu, Carolyn A Cohen, Daniel Leung, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
American Journal of Human Genetics
|
August 27, 2019
Heterozygous FOXN1 Variants Cause Low TRECs and Severe T Cell Lymphopenia, Revealing a Crucial Role of FOXN1 in Supporting Early Thymopoiesis
Marita Bosticardo, Yasuhiro Yamazaki, Jennifer Cowan, et al.
Page
of 93
Search research articles
Search
Showing results (891-900 of 922) with videos related to
Sort By:
Page
of 93
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Blood Advances
|
October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Joshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.
Journal of Medical Genetics
|
April 12, 2014
A meta-analysis identifies adolescent idiopathic scoliosis association with LBX1 locus in multiple ethnic groups
Douglas Londono, Ikuyo Kou, Todd A Johnson, et al.
Clinical Kidney Journal
|
March 24, 2025
Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases
Jeffery C H Chan, Eugene Yu-Hin Chan, Samuel M S Cheng, et al.
Kidney International Reports
|
November 29, 2023
Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
Daniel Leung, Eugene Yu-Hin Chan, Xiaofeng Mu, et al.
American Journal of Hematology
|
August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
Anthony R Mato, Lindsey E Roeker, John N Allan, et al.
The New England Journal of Medicine
|
June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
John C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Signal Transduction and Targeted Therapy
|
December 14, 2022
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents
Xiaofeng Mu, Carolyn A Cohen, Daniel Leung, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
American Journal of Human Genetics
|
August 27, 2019
Heterozygous FOXN1 Variants Cause Low TRECs and Severe T Cell Lymphopenia, Revealing a Crucial Role of FOXN1 in Supporting Early Thymopoiesis
Marita Bosticardo, Yasuhiro Yamazaki, Jennifer Cowan, et al.
Page
of 93